Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CCR1 | P32246 | 5/20 | 0.60 |
| ▸ | CCR8 | P51685 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.60 |
| ▸ | CCR5 | P51681 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | MMP2 | P08253 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | MMP8 | P22894 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313 | 0.98 | LMNA (1.00) | LMNACYP3A4CCR1CCR8MAPT | |
| SCHEMBL6513577 | 0.98 | LMNA (1.00) | LMNACYP3A4CCR1CCR8MAPT | |
| SCHEMBL1681333 | 0.96 | LMNA (0.96) | LMNACYP3A4CCR1CCR8MAPT | |
| SCHEMBL14576748 | 0.96 | LMNA (0.96) | LMNACYP3A4CCR1CCR8MAPT | |
| SCHEMBL8728454 | 0.96 | LMNA (0.96) | LMNACYP3A4CCR1CCR8MAPT | |
| SCHEMBL1003398 | 0.96 | LMNA (0.96) | LMNACYP3A4CCR1CCR8MAPT | |
| SCHEMBL15052618 | 0.96 | LMNA (0.96) | LMNACYP3A4CCR1CCR8MAPT | |
| SCHEMBL722331 | 0.96 | LMNA (0.96) | LMNACYP3A4CCR1CCR8MAPT | |
| SCHEMBL4447950 | 0.96 | LMNA (0.96) | LMNACYP3A4CCR1CCR8MAPT | |
| SCHEMBL4858817 | 0.96 | LMNA (0.96) | LMNACYP3A4CCR1CCR8MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080422-A | Aluminum-iron dissimilar metal organic framework material and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122080422-A | Aluminum-iron dissimilar metal organic framework material and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-119751468-A | Preparation method of qianli feilidine oxynitride | 成都普思生物科技股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-118530262-A | Linear terpyridine Cu complex and preparation method and application thereof | 苏州大学附属儿童医院 | 2024-08-23 | — | — | CN | disclosed |
| CN-117417357-A | Chiral phenanthroline-dinitrogen oxygen ligand, intermediate, preparation method thereof and application thereof in asymmetric catalytic reaction | 贵州大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-116459856-A | High-stability catalyst for hydrochlorination of acetylene as well as preparation method and application thereof | 鄂尔多斯市瀚博科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230102826-A1 | HEPARANASE INHIBITORS FOR TREATMENT OF DIABETES | WAYNE STATE UNIVERSITY (US) | 2023-03-30 | — | — | US | disclosed |
| US-11524026-B2 | Heparanase inhibitors for treatment of diabetes | WAYNE STATE UNIVERSITY (US) | 2022-12-13 | — | — | US | disclosed |
| CN-114133406-A | Conjugated organic complex of europium (III) and preparation method and application thereof | 南京邮电大学 | 2022-03-04 | — | — | CN | disclosed |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-23 | — | — | US | disclosed |
| US-9714441-B2 | Mediator-stabilized reagent compositions for use in biosensor electrodes | ABBOTT DIABETES CARE INC. (US) | 2017-07-25 | — | — | US | disclosed |
| WO-2016004156-A1 | COMPOSITIONS AND METHODS COMPRISING OSMIUM FOR TREATMENT OF CANCERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20140216949-A1 | Mediator-Stabilized Reagent Compositions for Use in Biosensor Electrodes | ABBOTT DIABETES CARE INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8696884-B2 | Mediator stabilized reagent compositions for use in biosensor electrodes | ABBOTT DIABETES CARE INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120325679-A1 | Mediator-Stabilized Reagent Compositions for Use in Biosensor Electrodes | ABBOTT DIABETES CARE INC. | 2012-12-27 | — | — | US | disclosed |
| US-8163146-B2 | Mediator stabilized reagent compositions for use in biosensor electrodes | ABBOTT DIABETES CARE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2205713-A1 | MEDIATOR-STABILIZED REAGENT COMPOSITIONS FOR USE IN BIOSENSOR ELECTRODES | Abbott Diabetes Care, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090095625-A1 | Mediator-Stabilized Reagent Compositions for Use in Biosensor Electrodes | ABBOTT DIABETES CARE INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2009049093-A1 | MEDIATOR-STABILIZED REAGENT COMPOSITIONS FOR USE IN BIOSENSOR ELECTRODES | ABBOTT DIABETES CARE INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20080206890-A1 | BIS(2,9-DI-TERT-BUTYL-1,10-PHENANTHROLINE)COPPER(I) COMPLEXES, METHODS OF SYNTHESIS, AND USES THEROF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206890-A1 | BIS(2,9-DI-TERT-BUTYL-1,10-PHENANTHROLINE)COPPER(I) COMPLEXES, METHODS OF SYNTHESIS, AND USES THEROF | TTI1, TTI2, TCOF1 | LMNA 2087/4885CYP3A4 4004/4885CCR1 2095/4885 |
| US-11524026-B2 | Heparanase inhibitors for treatment of diabetes | HPSE, ENGASE, HEXD | LMNA 2549/4885CYP3A4 1785/4885CCR1 1430/4885 |
| US-11179710-B2 | Direct palladium-catalyzed aromatic fluorination | KRAS, NRAS, DDT | LMNA 4383/4885CYP3A4 959/4885CCR1 1353/4885 |
| US-20230102826-A1 | HEPARANASE INHIBITORS FOR TREATMENT OF DIABETES | HPSE, ENGASE, HEXD | LMNA 2549/4885CYP3A4 1785/4885CCR1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.